New Research on COPD Patients in Home using FPH myAirvo

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

NEW RESEARCH SHOWS SIGNIFICANT BENEFITS FOR COPD PATIENTS IN THE
HOME USING FISHER & PAYKEL HEALTHCARE’S MYAIRVO

Auckland, New Zealand, 20 April 2018 - Fisher & Paykel Healthcare Corporation Limited
announced today that new research has been published in the International Journal of
COPD which demonstrates significant benefits of nasal high flow therapy for COPD* patients
using Fisher & Paykel Healthcare’s myAirvo device.

The study
1
, a randomised controlled trial undertaken in Denmark, investigated the long-term
effects of nasal high flow therapy for COPD patients already being treated with long-term
oxygen therapy.

The trial showed statistically significant results, with the primary outcome being a significant
reduction in patients’ exacerbation rate, or worsening of their condition (from 4.95 to 3.12 per
patient per year, p <0.001) for those being treated with nasal high flow therapy.

The study also showed for those patients using the myAirvo, that all cause hospitalisation
rates decreased from a rate of 1.39 to 0.79 per patient, over the course of the year, for those
who followed the protocol. Other positive results included the treatment group (myAirvo)
being better than the control group (standard care) in several quality of life assessments,
less breathlessness, better mobility and lower carbon dioxide retention levels for these
chronic patients.

The trial is the largest study of this treatment length to have been conducted in a home
environment and was led by researchers Line Storgaard and Dr Ulla Weinreich. It followed
200 patients with COPD on long-term oxygen for 16 hours or more per day over a period of
one year.

Vice President – Products & Technology at Fisher & Paykel Healthcare, Andrew Somervell
said, “It is positive to see such convincing outcomes for patients with COPD. We expect this
study to increase clinical interest in the myAirvo home respiratory device and encourage
clinical change and adoption around the world.”

This study adds to other positive results that were recently published in the Annals of the
American Thoracic Society. Led by Dr Kazuma Nagata of Kobe City Medical Centre General
Hospital, this study was a multi-centre trial in Japan with cross-over design, studying stable
COPD patients with hypercapnia
2
. This research also demonstrated a clinically significant
improvement in quality of life for patients (the mean total score improved by 7.8 points,
p<0.01), and a decrease in hypercapnia levels for patients with stable hypercapnic COPD.
As a result of the positive outcomes of this pilot trial, a larger multi-centre trial has
commenced.

Together, these new studies add to the growing body of evidence showing the efficacy of
nasal high flow therapy in the home for COPD patients using the myAirvo device.

*Chronic Obstructive Pulmonary Disease

1
Storgaard L, Hockey H, Laursen B, Weinreich U. Long-term effects of oxygen-enriched high-flow nasal cannula
treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis.

2018;13:1195-1205. Fisher & Paykel Healthcare provided the myAirvo devices and contributed to the funding of
this study.

2
Nagata K, Kikuchi T, Horie T, Shiraki A, Kitajima T, Kadowaki T et al. Domiciliary High-Flow Nasal Cannula
Oxygen Therapy for Patients with Stable Hypercapnic Chronic Obstructive Pulmonary Disease. A Multicenter
Randomized Crossover Trial. Ann Am Thorac Soc. 2018;15(4):432-439.


About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and
systems for use in respiratory care, acute care, surgery and the treatment of obstructive
sleep apnea. The company’s products are sold in over 120 countries worldwide. For more
information about the company, visit our website www.fphcare.com.


Ends

Contact:
Investors:
Marcus Driller
General Manager Corporate
marcus.driller@fphcare.co.nz
+64 (0) 27 578 9663
Media:
Rachel Reynolds
Senior Communications Manager
rachel.reynolds@fphcare.co.nz
+64 (0) 21 713 911





Caption: Fisher & Paykel Healthcare’s myAirvo is used for respiratory support in the home.